title: Patch testing with corticosteroid mixes in Europe. A multicentre study of the EECDRG.
abstract: This study investigated whether a corticosteroid mix containing tixocortol pivalate, budesonide, and hydrocortisone-17-butyrate could detect contact allergy to corticosteroids. 2 corticosteroid mixes, 1 with a high (mix I) and 1 with a low (mix II) concentration and the 3 individual constituents, each at 2 concentrations, were inserted into the standard series of 16 participating clinics. Tests were read on day (D) 3 or 4. 5432 patients were tested, and 110 (2.0%) had positive reactions to at least 1 of the 8 test preparations. Of the 8 preparations, mix I identified most allergic patients, followed by mix II, budesonide 0.10%, budesonide 0.002%, and tixocortol pivalate, both concentrations (1.0 and 0.10%) tracing the same number. With the mixes, 53.2-59.6% of tixocortol pivalate allergy was missed. 47 patients were allergic to either concentration of tixocortol pivalate, 25% of these only to 1.0% and another 25% only to 0.10%. Testing with mix I and tixocortol pivalate 0.10% picked up 98/110, testing with tixocortol pivalate 1.0% and 0.10% and budesonide 0.10% picked up 105/110. 3379 patients were read on both D3 or D4 as well as on D7. Without a late reading (D7), up to 30% of contact allergy to corticosteroid markers was missed.
authors.affiliation: Department of Occupational and Environmental Dermatology, Malmö University Hospital, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Isaksson
authors.forename: K E
authors.initials: KE
authors.lastname: Andersen
authors.forename: F M
authors.initials: FM
authors.lastname: Brandão
authors.forename: D P
authors.initials: DP
authors.lastname: Bruynzeel
authors.forename: M
authors.initials: M
authors.lastname: Bruze
authors.forename: J G
authors.initials: JG
authors.lastname: Camarasa
authors.forename: T
authors.initials: T
authors.lastname: Diepgen
authors.forename: G
authors.initials: G
authors.lastname: Ducombs
authors.forename: P J
authors.initials: PJ
authors.lastname: Frosch
authors.forename: A
authors.initials: A
authors.lastname: Goossens
authors.forename: A
authors.initials: A
authors.lastname: Lahti
authors.forename: T
authors.initials: T
authors.lastname: Menné
authors.forename: R J
authors.initials: RJ
authors.lastname: Rycroft
authors.forename: S
authors.initials: S
authors.lastname: Seidenari
authors.forename: S
authors.initials: S
authors.lastname: Shaw
authors.forename: A
authors.initials: A
authors.lastname: Tosti
authors.forename: J
authors.initials: J
authors.lastname: Wahlberg
authors.forename: I R
authors.initials: IR
authors.lastname: White
authors.forename: J D
authors.initials: JD
authors.lastname: Wilkinson
mesh_terms: D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D019819:Budesonide / Q000009:adverse effects; D017449:Dermatitis, Allergic Contact / Q000175:diagnosis* / Q000209:etiology; D004338:Drug Combinations; D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000209:etiology; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000009:adverse effects / Q000031:analogs & derivatives; D008297:Male; D010328:Patch Tests
chemical_list: D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; C007975:hydrocortisone-17-butyrate; D019819:Budesonide; C019112:tixocortol pivalate; D006854:Hydrocortisone